Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business day
Get my quote

Aromatic L-amino acid decarboxylase (AADC) deficiency: US-approved treatments and how Gulf families can access them

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

AADC deficiency: the short answer

For AADC deficiency, the US FDA has approved one medicine covered on this page, for a specific group of patients: Kebilidi. Where a medicine is not registered in your country, the treating hospital can ask the national regulator for permission to import it for one named patient. Reserve Meds is a digital health company that helps families and hospitals with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Kebilidi.
  • Gulf registration (checked 17 October 2026): see each medicine below.
  • Legal route: Treatment at a qualified center, after a specialist referral.
  • Price: Quote on request.

What is AADC deficiency?

AADC deficiency is a rare inherited disorder that affects how nerve cells send signals. Signs usually appear in the first six months of life. Babies may have feeding problems, weak muscle tone and sleep problems. Most have episodes called oculogyric crises, where the eyes roll upward without control. Developmental delay and movement problems such as dystonia are common.[1]

It is caused by variants in the DDC gene, which the body needs to make dopamine and serotonin. It is inherited in an autosomal recessive pattern: both parents usually carry one altered copy without symptoms. About 350 people with the condition had been reported in the medical literature.[1]

AADC deficiency in the Gulf

Doctors in the Gulf have published on this condition. A 2023 series of 16 patients from Middle East countries, with authors from Saudi Arabia, the UAE and Qatar, found that missed and delayed diagnoses were common and that almost all patients failed to reach major motor milestones. The authors called for earlier diagnosis, given the potential of gene therapy when given at an early age.[2]

Specialists at King Faisal Specialist Hospital and Research Centre in Riyadh described three Saudi patients, all with diagnostic delays linked to non-specific symptoms, low awareness and outsourced genetic testing. The first reported Emirati case, a boy with a new DDC variant, was published in 2022 by doctors in Dubai and Al Ain.[3, 4]

US FDA-approved medicines for AADC deficiency

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

  • Kebilidi (eladocagene exuparvovec-tneq)
    FDA-approved for adults and children with AADC deficiency. It is a one-time gene therapy given by infusion into a deep part of the brain (the putamen) during a planned neurosurgical procedure. Approved under accelerated approval, based on gross motor milestones at 48 weeks.[5, 6]
    US FDA approval: 13 November 2024. Gulf registers: Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Bahrain: not found in the NHRA registered medicines list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked.[7, 8, 9]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain

How families in the Gulf can access these medicines

For Kebilidi. These are made for one patient or given through a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center abroad that can give the treatment. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves the import. We cannot promise that a manufacturer will agree.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for AADC deficiency

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for AADC deficiency?

Yes. The medicine on this page has US FDA approval for a specific group of patients: Kebilidi. The exact conditions are in the US label and are summarized above. Your specialist decides whether it fits.

Is Kebilidi available in Saudi Arabia or the UAE?

Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Bahrain: not found in the NHRA registered medicines list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked. A listing in Abu Dhabi does not show federal UAE status, which we could not verify.

How can a family in the Gulf get Kebilidi?

It is given at a qualified center. Your specialist refers the patient, the center checks eligibility, and the family plans funding and travel. A local hospital can only give it if the manufacturer agrees to supply it and the regulator approves the import.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

How is AADC deficiency diagnosed?

Diagnosis rests on a specialist's assessment and genetic testing of the DDC gene. The Saudi case reports describe delays when genetic tests were sent abroad, so ask your specialist early about testing.

Sources for the last answer: [1, 3]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

  1. MedlinePlus Genetics (US National Library of Medicine): Aromatic l-amino acid decarboxylase deficiency
  2. Abukhaled M, et al. Aromatic L-amino acid decarboxylase deficiency in countries in the Middle East: a case series and literature review. Eur J Pediatr. 2023;182(6):2535-2545 (PubMed 36928758)
  3. Abukhaled M, et al. Case report: AADC deficiency in three patient cases from the Kingdom of Saudi Arabia. Front Pediatr. 2023 (PubMed 36727005)
  4. Babiker MOE, et al. First case report of an Emirati child with a novel gene variant causing AADC deficiency. Front Pediatr. 2022 (PubMed 36110109)
  5. FDA: 2024 Biological License Application Approvals (CBER)
  6. DailyMed: KEBILIDI (eladocagene exuparvovec-tneq) US prescribing information (label version 11 June 2026)
  7. SFDA: Drugs List, public register (all 9,173 entries checked by brand and generic name on 17 October 2026)
  8. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  9. NHRA Bahrain: Registered Medicine Price List, version dated 7 September 2026 (Excel, 5,560 entries)
  10. SFDA: Special Access Program (SAP) guidance, version 1.0
  11. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp